Status:
COMPLETED
Treatment of Early Stage Renal Failure With Active Vitamin D or a Phosphate Binder.
Lead Sponsor:
Helse Stavanger HF
Collaborating Sponsors:
Rikshospitalet University Hospital
Conditions:
Kidney Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Patients with reduced renal function normally develop hyperparathyroidism, which in turn is associated with increased cardiovascular risk and de-calcification. Hyperparathyroidism may be enhanced by a...
Eligibility Criteria
Inclusion
- Renal failure stage 3B
- 25(OH)vitamin D level above 50 nmol/l
- Age over 18 years
- Written consent
Exclusion
- Major surgery during the previous 6 months
- Myocardial infarct during the previous 6 months
- Unstable heart failure
- Ongoing treatment for any malignancy
- History of frequent infections
- Pregnancy
- Ongoing treatment with steroids, lithium or biphosphonates
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT01231438
Start Date
October 1 2010
End Date
March 1 2011
Last Update
November 9 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo Universitetssykehus Rikshospitalet
Oslo, Norway, NO-0372
2
Stavanger University Hospital
Stavanger, Norway, NO-4011